Regulatory Milestone Propels ImmunityBio (IBRX) Stock Upward
After receiving a significant regulatory approval, ImmunityBio, Inc. (NASDAQ: IBRX) saw a sharp rise in the value of its shares. IBRX shares rose 18.25% to $3.96 as of the most recent market check. In reaction to the FDA’s approval of an Expanded Access Program (EAP) that will enable a different source of Bacillus Calmette-Guérin (BCG), …
Regulatory Milestone Propels ImmunityBio (IBRX) Stock Upward Read More »